Despite continuing normalization two years into the COVID-19 pandemic, 2022 was shaping up to be a year of significant downturn in biopharmaceutical merger-and-acquisition activity. The year closed out with a deal big enough – Amgen, Inc. acquiring Horizon Therapeutics plc for $27.8bn – to shift the full-year statistics. Even with that transaction, however, M&A deal volume, total reported value and total average value dropped substantially from 2021.
The difference really was just a matter of degree, though. Factoring in the Amgen buyout, M&A total value declined 40% from 2021, while average deal value (meaning the reported amount paid, without factoring in any downstream payments such as milestone fees or contingent value rights) fell by 32%. (Also see "Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover" - Scrip, 12 December, 2022
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?